Shailender Thapliyal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shailender Thapliyal has a total of 94 co-authors. Here are the top co-authors by number of shared publications:
- Sarvesh Rustagi
Uttaranchal University
8 shared publications Kailash Bisht
Uttaranchal University
7 shared publications- Sumira Malik
Amity University
7 shared publications - Jutishna Bora
Amity Institute of Biotechnology Amity University Jharkhand Ranchi India
5 shared publications - Saravanan P
Uttaranchal University
5 shared publications - Subham Preetam
Department of Robotics and Mechatronics Engineering, Daegu Gyeongbuk Institute of Science and Technology (DGIST), Dalseong‑gun, Daegu, South Korea
5 shared publications
Latest Publications
- Open Access
- 30 September 2026
- Published by Oriental Scientific Publishing Company in Biomedical and Pharmacology Journal
- Vol. 3 (19) , 2192-2207
Polycystic Ovarian Syndrome and Diabetes Mellitus: A Bidirectional Endocrine Disorder
Polycystic ovarian syndrome (PCOS) is a typical hormonal imbalance that affects women who are ready to procreate. In polycystic ovarian syndrome, the ovaries may generate an abundance of small fluid-filled cysts yet fail to release eggs regularly. A high amount of the male hormone produced by polycystic ovarian syndrome delays and unbalances the female body's menstrual cycle. Polycystic Ovarian Syndrome usually synchronizes with a variety of dysglycemia conditions, from Impaired Glucose Tolerance (IGT) towards the commencement of Type 2 Diabetes Mellitus (T2DM), and often appears in greater levels than in healthy women. This synchronism of polycystic ovarian syndrome is solely associated with prevalent pathogenic pathways connecting the two distinct phenomena, like Insulin Resistance (IR), genetics, neuroendocrine, lifestyle/environment, and obesity, which are the prime risk factors that aid in the development of Polycystic Ovarian Syndrome (PCOS). This review research seeks to determine if polycystic ovarian syndrome (PCOS) and type 2 Diabetes Mellitus (T2DM) are related.
- 30 September 2026
- Published by Oriental Scientific Publishing Company in Biomedical and Pharmacology Journal
- Vol. 3 (19) , 2192-2207
Open AccessPolycystic Ovarian Syndrome and Diabetes Mellitus: A Bidirectional Endocrine Disorder
Polycystic ovarian syndrome (PCOS) is a typical hormonal imbalance that affects women who are ready to procreate. In polycystic ovarian syndrome, the ovaries may generate an abundance of small fluid-filled cysts yet fail to release eggs regularly. A high amount of the male hormone produced by polycystic ovarian syndrome delays and unbalances the female body's menstrual cycle. Polycystic Ovarian Syndrome usually synchronizes with a variety of dysglycemia conditions, from Impaired Glucose Tolerance (IGT) towards the commencement of Type 2 Diabetes Mellitus (T2DM), and often appears in greater levels than in healthy women. This synchronism of polycystic ovarian syndrome is solely associated with prevalent pathogenic pathways connecting the two distinct phenomena, like Insulin Resistance (IR), genetics, neuroendocrine, lifestyle/environment, and obesity, which are the prime risk factors that aid in the development of Polycystic Ovarian Syndrome (PCOS). This review research seeks to determine if polycystic ovarian syndrome (PCOS) and type 2 Diabetes Mellitus (T2DM) are related.
- 14 September 2026
- Published by Bentham Science Publishers Ltd. in MicroRNA
- Vol. 15, 1-15
The Role of microRNA-25 and microRNA-30 in Diabetes and Its Complications: Mechanisms, Biomarker Potential, and Therapeutic Implications
Diabetes is one of the most well-defined and complicated metabolic diseases, which is the cause of various dysfunctions in the body. Along with the elderly group, its prevalence in children and adolescents is steadily rising. There are two major types of diabetes mellitus: type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM). T1DM is a chronic autoimmune disease characterised by insulin deficiency, leading to hyperglycemia. At the same time, T2DM is a heterogeneous chronic disorder characterised by the body's resistance to insulin and the pancreatic cells' inability to produce sufficient insulin to compensate for this resistance. The involvement of molecules such as microRNAs in regulating the disease provides a vast and noble field of study for diabetes mellitus. The microRNAs are small (~=21-23 nucleotides), endogenous, non-coding RNAs that interact with the 3' UTR of the targeted mRNA to cause gene silencing and translational repression. The hallmark of diabetes is increased reactive oxygen species (ROS) and Nox4 expression along with reduced MiR-25 expression, leading to progression of diabetic neuropathy (DN). Upregulated MiR-25 acts as a protective factor against Diabetic neuropathy. Similarly, the molecule MiR-30 is involved in cardiac dysfunction and diabetic neuropathy. Also, 40% of the patients with diabetes mellitus are affected by Diabetic Kidney Disease (DKD), which is a common microvascular complication. Studies have found that MiR-30e-5p plays a significant role in the pathogenesis of DKD. DKD patients seem to have downregulated MiR-30e-5p. This review summarises regulatory studies on miRNAs in diabetes. Furthermore, recent advances in understanding regulatory mechanisms have opened new avenues for targeted therapeutic strategies in diabetic complications.
- 14 September 2026
- Published by Bentham Science Publishers Ltd. in MicroRNA
- Vol. 15, 1-15
The Role of microRNA-25 and microRNA-30 in Diabetes and Its Complications: Mechanisms, Biomarker Potential, and Therapeutic Implications
Diabetes is one of the most well-defined and complicated metabolic diseases, which is the cause of various dysfunctions in the body. Along with the elderly group, its prevalence in children and adolescents is steadily rising. There are two major types of diabetes mellitus: type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM). T1DM is a chronic autoimmune disease characterised by insulin deficiency, leading to hyperglycemia. At the same time, T2DM is a heterogeneous chronic disorder characterised by the body's resistance to insulin and the pancreatic cells' inability to produce sufficient insulin to compensate for this resistance. The involvement of molecules such as microRNAs in regulating the disease provides a vast and noble field of study for diabetes mellitus. The microRNAs are small (~=21-23 nucleotides), endogenous, non-coding RNAs that interact with the 3' UTR of the targeted mRNA to cause gene silencing and translational repression. The hallmark of diabetes is increased reactive oxygen species (ROS) and Nox4 expression along with reduced MiR-25 expression, leading to progression of diabetic neuropathy (DN). Upregulated MiR-25 acts as a protective factor against Diabetic neuropathy. Similarly, the molecule MiR-30 is involved in cardiac dysfunction and diabetic neuropathy. Also, 40% of the patients with diabetes mellitus are affected by Diabetic Kidney Disease (DKD), which is a common microvascular complication. Studies have found that MiR-30e-5p plays a significant role in the pathogenesis of DKD. DKD patients seem to have downregulated MiR-30e-5p. This review summarises regulatory studies on miRNAs in diabetes. Furthermore, recent advances in understanding regulatory mechanisms have opened new avenues for targeted therapeutic strategies in diabetic complications.
- 31 August 2026
- Published by Wiley in Water Environment Research
- Vol. 98 (9) , e70556
Engineering Microbial–Electrochemical Interfaces for Sustainable Water Purification
Electrofusion is an emerging frontier in sustainable water purification, integrating microbial activity with electrochemical processes to achieve efficient and eco‐friendly treatment. Bioeletrofusion improves microbial fuel cells (MFCs) and bioelectrochemical systems by allowing controlled membrane fusion in electric fields. This makes electron transfer pathways better and increases catalytic efficiency. This enables superior degradation of organic pollutants, pathogen elimination, and recovery of clean water with minimal chemical use. The technology stands out for its dual functionality: treating diverse municipal and industrial effluents while simultaneously generating bioelectricity, thereby advancing circular economy principles. With its low energy demand and adaptability, electrofusion offers a scalable solution well suited for decentralized and resilient water infrastructure. Current research focuses on optimizing electrode materials, engineering microbial consortia, and integrating smart monitoring systems to support real‐world deployment. Collectively, bioelectrofusion holds significant promise for transforming wastewater treatment and expanding access to clean water worldwide.
- 31 August 2026
- Published by Wiley in Water Environment Research
- Vol. 98 (9) , e70556
Engineering Microbial–Electrochemical Interfaces for Sustainable Water Purification
Electrofusion is an emerging frontier in sustainable water purification, integrating microbial activity with electrochemical processes to achieve efficient and eco‐friendly treatment. Bioeletrofusion improves microbial fuel cells (MFCs) and bioelectrochemical systems by allowing controlled membrane fusion in electric fields. This makes electron transfer pathways better and increases catalytic efficiency. This enables superior degradation of organic pollutants, pathogen elimination, and recovery of clean water with minimal chemical use. The technology stands out for its dual functionality: treating diverse municipal and industrial effluents while simultaneously generating bioelectricity, thereby advancing circular economy principles. With its low energy demand and adaptability, electrofusion offers a scalable solution well suited for decentralized and resilient water infrastructure. Current research focuses on optimizing electrode materials, engineering microbial consortia, and integrating smart monitoring systems to support real‐world deployment. Collectively, bioelectrofusion holds significant promise for transforming wastewater treatment and expanding access to clean water worldwide.
- 26 June 2026
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 217 (3)
Comments on: Predictors of pathologic complete response in early-stage triple-negative breast cancer treated with neoadjuvant chemo-immunotherapy
This correspondence comments on LeVee et al.'s real-world study of neoadjuvant chemo-immunotherapy in early-stage triple-negative breast cancer. We highlight diabetes as a potentially modifiable host-state factor influencing pathologic complete response and propose a metabolic immunotherapy-readiness framework integrating glycaemic control, treatment delivery, endocrine monitoring, and equity-focused implementation. This perspective aims to support globally applicable strategies for improving chemo-immunotherapy effectiveness and access.
- 26 June 2026
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 217 (3)
Comments on: Predictors of pathologic complete response in early-stage triple-negative breast cancer treated with neoadjuvant chemo-immunotherapy
This correspondence comments on LeVee et al.'s real-world study of neoadjuvant chemo-immunotherapy in early-stage triple-negative breast cancer. We highlight diabetes as a potentially modifiable host-state factor influencing pathologic complete response and propose a metabolic immunotherapy-readiness framework integrating glycaemic control, treatment delivery, endocrine monitoring, and equity-focused implementation. This perspective aims to support globally applicable strategies for improving chemo-immunotherapy effectiveness and access.
- 10 June 2026
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 14 (27) , 8352-8371
3D-printed lab-on-chip platforms for the detection of neurodegenerative diseases: opportunities and challenges
3D-printed lab-on-chip platform for neurodegenerative disease detection, integrating microfluidic sample processing with advanced biosensing strategies for rapid biomarker analysis and diagnosis.
- 10 June 2026
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 14 (27) , 8352-8371
3D-printed lab-on-chip platforms for the detection of neurodegenerative diseases: opportunities and challenges
3D-printed lab-on-chip platform for neurodegenerative disease detection, integrating microfluidic sample processing with advanced biosensing strategies for rapid biomarker analysis and diagnosis.
- 15 May 2026
- Published by Elsevier in Food Bioscience
- Vol. 81
Mitigating microplastic contamination in the food chain via microalgae: Sequestration and bioplastic production
- 15 May 2026
- Published by Elsevier in Food Bioscience
- Vol. 81
Mitigating microplastic contamination in the food chain via microalgae: Sequestration and bioplastic production
- Open Access
- 3 March 2026
- Published by Elsevier in Ultrasonics Sonochemistry
- Vol. 128, 107807
Mechanistic insights into sonication-assisted cold plasma treatments for improved microbial decontamination and quality maintenance in perishable foods
- 3 March 2026
- Published by Elsevier in Ultrasonics Sonochemistry
- Vol. 128, 107807
Open AccessMechanistic insights into sonication-assisted cold plasma treatments for improved microbial decontamination and quality maintenance in perishable foods
- Open Access
- 12 December 2025
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 15 (58) , 50379-50391
Harnessing limonene and Fenton's reagent for enhanced micro- and nanoplastic removal from aquatic systems
A synergistic limonene–Fenton strategy combining adsorption and oxidative degradation offers a sustainable approach for removing microplastics and nanoplastics.
- 12 December 2025
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 15 (58) , 50379-50391
Open AccessHarnessing limonene and Fenton's reagent for enhanced micro- and nanoplastic removal from aquatic systems
A synergistic limonene–Fenton strategy combining adsorption and oxidative degradation offers a sustainable approach for removing microplastics and nanoplastics.
- Open Access
- 9 December 2025
- Published by Royal Society of Chemistry (RSC) in Nanoscale Advances
- Vol. 8 (2) , 458-478
Targeting brain tumours with precision: advances in magnetic nanoparticle therapy
Schematic overview of magnetic nanoparticles in brain cancer therapy. MNPs enable magnetic hyperthermia, targeted drug delivery, and MRI imaging, while facing challenges in BBB penetration, toxicity, biodistribution, and long-term biocompatibility.
- 9 December 2025
- Published by Royal Society of Chemistry (RSC) in Nanoscale Advances
- Vol. 8 (2) , 458-478
Open AccessTargeting brain tumours with precision: advances in magnetic nanoparticle therapy
Schematic overview of magnetic nanoparticles in brain cancer therapy. MNPs enable magnetic hyperthermia, targeted drug delivery, and MRI imaging, while facing challenges in BBB penetration, toxicity, biodistribution, and long-term biocompatibility.
- 1 October 2025
- Published by Springer Nature
- p. 457-471
Microsoft HoloLens: Blockchain Assisted Wearable Augmented Reality in a Safety Critical System
- 1 October 2025
- Published by Springer Nature
- p. 457-471
Microsoft HoloLens: Blockchain Assisted Wearable Augmented Reality in a Safety Critical System